Deep Genomics news
Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today that its Founder and Chief Executive Officer, Brendan Frey, Ph.D., F.R.S.C., will participate in a panel discussion during the Citi PCA – Private Company Digital Health Conference *VIRTUAL* on May 20, 2021.
Details:
- Session: Artificial Intelligence in Drug Discovery
- Date and time: Thursday, May 20, 2021 from 1:3
January 6, 2022. Deep Genomics, the leading AI RNA therapeutics company, today announced that its Founder and CEO, Brendan Frey, PhD, FRSC, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 10:00 a.m. EST.
The presentation will be available as a live webcast through the J.P. Morgan Healthcare Conference portal.
About Deep Genomics
Deep Genomics combines artificial intelligence
Deep Genomics, the leading AI therapeutics company, welcomes Tal Zaks, M.D., Ph.D., to its Strategic Advisory Board, effective today. Deep Genomics uses AI and machine learning to program and prioritize transformational nucleotide-based therapeutics for genetic diseases.
As Chief Medical Officer at Moderna, Zaks successfully led a team that pioneered the field of mRNA therapeutics and drove extraordinary growth, with more than two dozen preclinical and clinical programs advanced durin
Mila, the Quebec Artificial Intelligence Institute, today announced the start of a partnership with Deep Genomics, a leading company in therapeutic artificial intelligence treatments. This collaboration will allow the company to join Mila`s community and to take advantage of the recruitment activities offered by the research institute. Deep Genomics uses AI and machine learning to program and prioritize transformational therapeutics for genetic diseases where unmet medical needs persist. The
- Company expands AI discovery platform for ‘Programmable’ RNA therapeutics and supports advancement of its portfolio into the clinic
- Oversubscribed round led by SoftBank Vision Fund 2, with CPP Investments, Fidelity Management & Research Company LLC, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures
Deep Genomics, the leading artificial intelligence (AI) therapeutics